Arcturus Therapeutics Files Q1 2025 10-Q
Ticker: ARCT · Form: 10-Q · Filed: May 12, 2025 · CIK: 1768224
| Field | Detail |
|---|---|
| Company | Arcturus Therapeutics Holdings Inc. (ARCT) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: biotech, 10-Q, clinical-trials, collaboration
Related Tickers: CRSP, EDIT, BEAM
TL;DR
**ARCT Q1 2025 10-Q FILED: Check financials & COVID vaccine progress.**
AI Summary
Arcturus Therapeutics Holdings Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, including details on its COVID-19 vaccine development and collaborations. Key financial data and operational highlights are presented within this quarterly report.
Why It Matters
This filing provides investors and stakeholders with an update on Arcturus Therapeutics' financial health and operational progress, crucial for understanding the company's trajectory in the competitive biotech sector.
Risk Assessment
Risk Level: medium — Biotechnology companies like Arcturus Therapeutics face inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2024-12-31 — Previous Fiscal Year End (Provides a point of comparison for retained earnings.)
- 2024-03-31 — Prior Year Quarter End (Used for property lease guarantee comparison.)
Key Players & Entities
- Arcturus Therapeutics Holdings Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of the reporting period
- Seqirus Inc. (company) — Mentioned in relation to a collaboration agreement
- Biomedical Advanced Research and Development Authority (company) — Received funding or engaged in collaboration
- CSL Collaboration Agreement (company) — Related to collaboration revenue
FAQ
What is the primary focus of Arcturus Therapeutics' research and development as highlighted in this 10-Q?
The filing mentions Arcturus Therapeutics' involvement in COVID-19 vaccine development and other therapeutic areas, with specific collaborations like the one with Seqirus Inc.
What significant collaborations or agreements are mentioned in the filing?
The filing references a Research Collaboration and License Agreement with Seqirus Inc. and a CSL Collaboration Agreement, indicating partnerships in their development pipeline.
What is the reporting period for this 10-Q filing?
The 10-Q filing covers the period ending March 31, 2025.
Are there any specific government or authority collaborations mentioned?
Yes, the filing indicates interactions with the Biomedical Advanced Research and Development Authority.
What type of financial reporting is this document?
This document is a 10-Q, which is a quarterly report filed by public companies with the SEC.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Arcturus Therapeutics Holdings Inc. (ARCT).